Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 20, 2021 | May 24, 2021 |
| Moderna, Inc.MRNA · Entity 2025 | President | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 20, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-05-19 | Direct | 20,000 |
Reported balance
After 2021-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.
Moderna, Inc.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,562,029 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-14 · Exercise / conversion · Acquired 76,453 · Balance 1,566,152 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 2 · 2026-09-14 · Sale · Disposed 40,294 · Balance 1,525,858 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 76,452 · Balance 1,602,310 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. Row 4 · 2026-09-15 · Sale · Disposed 40,281 · Balance 1,562,029 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 382,262 |
Reported balance
After 2026-09-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-14 · Exercise / conversion · Disposed 76,453 · Balance 382,262 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | 305,810 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 76,452 · Balance 305,810 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F5: This option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy Valhalla, LLC | 4,116 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,116 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 151,933 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 151,933 F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 713 | $402.09 | $286,690.17 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 12 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615,559 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $401.58 to $402.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 725 | $400.84 | $290,609.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 11 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616,272 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $400.41 to $401.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 800 | $399.16 | $319,328.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 10 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616,997 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $398.51 to $399.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 200 | $396.89 | $79,378.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 9 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,617,797 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $396.88 to $396.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 400 | $396.28 | $158,512.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,617,997 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $395.87 to $396.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 300 | $395.11 | $118,533.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,618,397 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $394.72 to $395.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 200 | $393.68 | $78,736.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,618,697 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $393.36 to $394.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 400 | $392.68 | $157,072.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,618,897 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $392.11 to $393.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $390.11 | $1,950,550.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,619,297 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 300 | $389.39 | $116,817.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624,297 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $389.02 to $390.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:20 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $10.90 | $54,500.00 |
DisclosureSEC source: 0001127602-21-024308 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-21-023784 · form4.xml · derivative · entry 10 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001127602-21-023784 · form4.xml · derivative · entry 9 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,972 Underlying: Common Stock · 5,000 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 15,000 | $405.00 | $6,075,000.00 |
DisclosureSEC source: 0001127602-21-023784 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-21-023784 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $10.90 | $54,500.00 |
DisclosureSEC source: 0001127602-21-023784 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001127602-21-023784 · form4.xml · derivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,972 Underlying: Common Stock · 5,000 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $400.00 | $2,000,000.00 |
DisclosureSEC source: 0001127602-21-023784 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $10.90 | $54,500.00 |
DisclosureSEC source: 0001127602-21-023784 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 20:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-21-023063 · form4.xml · derivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 20:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $348.77 | $3,487,700.00 |
DisclosureSEC source: 0001127602-21-023063 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 20:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-21-023063 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,619,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-21-023063 · form4.xml · derivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $360.15 | $3,601,500.00 |
DisclosureSEC source: 0001127602-21-023063 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-21-023063 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,619,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · derivative · entry 25 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,972 Underlying: Common Stock · 5,000 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F18 · derivative.exercise_date: 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,000 | $351.99 | $1,759,950.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 20 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $10.90 | $54,500.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 19 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · derivative · entry 24 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F19 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · derivative · entry 23 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,972 Underlying: Common Stock · 5,000 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F18 · derivative.exercise_date: 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 208 | $348.41 | $72,469.28 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 18 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,597 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $348.24 to $348.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 474 | $347.83 | $164,871.42 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 17 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,609,805 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $347.20 to $348.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 400 | $346.52 | $138,608.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 16 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,610,279 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $346.14 to $346.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 401 | $345.51 | $138,549.51 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 15 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,610,679 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $344.93 to $345.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 400 | $342.76 | $137,104.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 14 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,611,080 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $342.48 to $343.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 297 | $341.98 | $101,568.06 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 13 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,611,480 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $341.40 to $342.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 300 | $340.65 | $102,195.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 12 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,611,777 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $340.16 to $341.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 854 | $338.90 | $289,420.60 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 11 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,612,077 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $338.59 to $339.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,333 | $338.07 | $450,647.31 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 10 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,612,931 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $337.50 to $338.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 600 | $336.81 | $202,086.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 9 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614,264 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $336.40 to $337.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 800 | $335.36 | $268,288.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614,864 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $334.83 to $335.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,200 | $334.14 | $400,968.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615,664 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $333.75 to $334.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,333 | $332.15 | $442,755.95 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616,864 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $331.78 to $332.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,900 | $330.96 | $1,952,664.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,618,197 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $330.75 to $331.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 400 | $329.91 | $131,964.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624,097 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $329.40 to $330.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 100 | $327.96 | $32,796.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624,497 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,624,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 22:14 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 5,000 | $10.90 | $54,500.00 |
DisclosureSEC source: 0001127602-21-022518 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,614,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 20:22 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-21-021926 · form4.xml · derivative · entry 10 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.